# US 2004/0072773 A1 · Novel functions for dp214

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072773 A1
- Document ID: US20040072773A1
- Status: Published application
- Kind: A1
- Application number: 10/363,426
- Filed: 2003-02-28
- Published: 2004-04-15
- Earliest claimed: 2000-09-01
- Inventors: Cord E. Dohrmann
- Web page: https://patentgrep.com/patent/US20040072773A1

## CPC

- A61K 38/1709: {from mammals}
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses polynucleotides which identify and encode pDP214 as well as novel functions for the DP214 gene family (pDP214) which are specifically expressed specifically expressed in the mesenchyme of the developing pancreas, in the lung, the stomach, the kidney and specific areas of the ectoderm such as ectodermal ridge and hair follicles. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding pDP214 and a method for producing pDP214. The invention also provide for agonists, antibodies, or antagonists specifically binding, pDP214, and their, use, in the prevention and treatment of diseases associated with the expression of pDP214. Additionally, the invention provides for the use or antisense molecules to polynucleotides encoding pDP214 for the treatment or diseases associated with the expression of pDP214. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding pDP214.

## Claims

### Claim 1

A pharmaceutical composition comprising as an active agent a nucleic acid molecule of the DP214 gene family or a polypeptide encoded thereby or a fragment or variant of said nucleic acid molecule or said polypeptide or an antibody, aptamer or other receptor recognizing a nucleic acid molecule of the DP214 gene family or a polypeptide encoded thereby.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the nucleic acid is a chicken DP214 nucleic acid or a human homolog or a fragment or a variant thereof.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or 2 wherein the nucleic acid molecule is a C-type lectin domain comprising the sequence which is designated as CLT1 in FIG. 3 or a human homolog or a fragment or a variant thereof.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1-3, wherein the nucleic acid molecule encodes a polypeptide expressed in specific tissues, wherein said nucleic acid molecule
(a) hybridizes at 55° C. in a solution containing 1×SSC and 0.1% SDS to a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO: 1 or the complementary strand thereof;
(b) it is degenerate with respect to the nucleic acid molecule of (a)
(c) encodes a polypeptide which is at least 85%, preferably at least 90%, more preferably at least 95%, more preferably at least 98% and up to 99.6% identical to SEQ ID NO: 2, or
(d) differs from the nucleic acid molecule of (a) to (c) by mutation and wherein said mutation causes an alteration, deletion, duplication or premature stop in the encoded Polypeptide.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1-4 wherein the nucleic acid molecule is a DNA molecule, particularly a cDNA or a genomic DNA.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1-5 wherein the nucleic acid molecule is associated with differentiation or developmental control, particularly associated with the development of the pancreas, more particularly causally associated with the development of the pancreas in mammals.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1-6 wherein the nucleic acid molecule encodes a protein that is expressed in the mesenchyme of the developing pancreas, in the lung, the stomach, the kidney or/and specific areas of the ectoderm such as ectodermal ridge and hair follicles.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1-7 wherein the nucleic acid molecule is a recombinant or synthetic and optionally modified nucleic acid molecule.

### Claim 9 (depends on 8)

The composition of claim 8 wherein the recombinant nucleic acid molecule is a vector, particularly an expression vector.

### Claim 10 (depends on 1)

The composition of claim 1 wherein the active ingredient is an antibody, fragment or derivative thereof or an aptamer or another receptor specifically recognizing a nucleic acid molecule of the DP214 family or a polypeptide encoded thereby.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition of any one of claims 1-10 wherein said polypeptide is a recombinant polypeptide.

### Claim 12 (depends on 11)

The composition of claim 11 wherein said polypeptide is a fusion polypeptide.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition of any one of claims 1-10 wherein said nucleic acid molecule is selected from hybridization probes, primers and antisense oligonucleotides.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1-13 for diagnostic applications.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any one of claims 1-13 for therapeutic applications.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The composition of any one of claims 1-15 for the manufacture of an agent for the diagnosis, monitoring, prevention or treatment of diseases or disorders of the pancreas, lung, stomach, kidney, skin, and/or appendages particularly in a mammal.

### Claim 17 (depends on 16)

The composition of claim 16 wherein the disease or disorder is a pancreatic disease or disorder including metabolic disorders associated with an endocrine dysfunction such as diabetes or adipositas.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12)

A non-human animal expressing the polypeptide of claim 11 or the fusion protein of claim 12, transfected with the vector of claim 9, or comprising the nucleic acid molecule of any one of claims 1 to 8.

### Claim 19 (depends on 18)

The animal of claim 18 wherein the expression of the DP214 polypeptide is modified, e.g. increased or reduced.

### Claim 20

A recombinant host cell exhibiting a modified, e.g. increased or reduced expression of a DP214 polypeptide.

### Claim 21 (depends on 20)

The cell of claim 20 which is a human cell.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21)

Use of the nucleic acid molecule of any one of claims 1 to 8, the vector of claim 9, the host or host cell of any one of claims 18-21, the polypeptide of claim 11, the fusion protein of claim 12, the antibody, fragment or derivative thereof, aptamer or receptor of claim 10 or the anti-sense oligonucleotide of claim 13 for controlling the function of a gene and/or a gene product which is influenced and/or modified by a DP214 polypeptide.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

Use of the composition of any one of claims 1-17, for the manufacture of an agent for detecting and/or verifying, for the treatment, alleviation and/or prevention of diseases or disorders of the pancreas (such as diabetes), and related diseases and disorders (such as adipositas), of the lung, of the stomach, of the kidney, of the skin and of appendages and others in cells, cell masses, organs and/or subjects.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21)

Use of the nucleic acid molecule of any one of claims 1 to 8, the vector of claim 9, the host or host cell of any one of claims 18-21, the polypeptide of claim 11, the fusion protein of claim 12, the antibody, fragment or derivative thereof, aptamer or receptor of claim 10 or the anti-sense oligonucleotide of claim 13 for identifying substances capable of interacting with a DP214 polypeptide.

### Claim 25

A method of identifying a polypeptide involved in diseases and disorders, for example, but not limited to, of the pancreas (such as diabetes), and related diseases and disorders (such as adipositas), of the pancreas, of the lung, of the stomach, of the kidney, of the skin or of appendages, and others in a mammal comprising the steps of
(a) contacting a collection of (poly)peptides with a DP214 polypeptide or a fragment thereof under conditions that allow binding of said (poly)peptides;
(b) removing (poly)peptides from said collection of (poly)peptides that do not bind in step (a); and
(c) identifying (poly)peptides that bind to said DP214 polypeptide or the fragment thereof.

### Claim 26

A method of screening for an agent which modulates the interaction of a DP214 polypeptide with a binding target/agent, comprising the steps of
(a) incubating a mixture comprising
(aa) a DP214 polypeptide, or a fragment thereof;
(ab) a binding target/agent of said DP214 polypeptide or fragment thereof; and
(ac) a candidate agent
under conditions whereby said polypeptide or fragment thereof specifically binds to said binding target/agent at a reference affinity;
(b) detecting the binding affinity of said DP214 polypeptide or fragment thereof to said binding target to determine an (candidate) agent-biased affinity; and
(c) determining a difference between (candidate) agent-biased affinity and the reference affinity.

### Claim 27 (depends on 25, 26)

A method of producing a composition comprising the (poly)peptide identified by the method of claim 25 or the agent identified by the method of claim 26 with a pharmaceutically acceptable carrier and/or diluent.

### Claim 28 (depends on 25, 27)

The method of claim 27 wherein said composition is a pharmaceutical composition for preventing, alleviating or treating diseases and disorders (such as adipositas), of the lung, of the stomach, of the kidney, of the skin and of appendages and others in cells, cell masses, organs and/or subjects, and other diseases and disorders, particularly as identified in claim 25.

### Claim 29 (depends on 25, 26)

Use of a (poly)peptide as identified in claim 25 or of an agent as identified by the method of claim 26 for the preparation of a pharmaceutical composition for the treatment, alleviation and/or prevention of diseases or disorders of the pancreas (such as diabetes), and related diseases and disorders (such as adipositas), of the lung, of the stomach, of the kidney, of the skin and of appendages and others in cells, cell masses, organs and/or subjects.

### Claim 30

Use of a nucleic acid molecule as depicted in SEQ ID, NO: 1 or a homolog or a a fragment thereof for the preparation of a transgenic non-human animal which over- or underexpresses the corresponding gene product or a fragment thereof.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21)

Kit comprising at least one of
(a) a nucleic acid molecule of any one of claims 1 to 8;
(b) a vector of claim 9;
(c) a host or host cell of any one of claims 18-21;
(d) a polypeptide of claim 11;
(e) a fusion protein of claim 12;
(f) an antibody or a fragment or derivative thereof or an aritiserum, an aptamer or a receptor of claim 10; and
(g) an anti-sense oligonucleotide of claim 13.
